Sign in
Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
Journal article   Peer reviewed

Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Ronan Swords, Robert H. Collins, Gabriel N. Mannis, Daniel A. Pollyea, …
Clinical lymphoma, myeloma and leukemia, Vol.18, pp.S204-S205
2018-09

Metrics

17 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.103 Blood Disorders
1.103.155 Acute Myeloid Leukemia
Web Of Science research areas
Hematology
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details